Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05926687 · ClinicalTrials.gov registry record · Phase 2
Optimizing Outcomes for Young Autistic Children
A Phase 2 study of Autism Spectrum Disorder and Autism, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 184
- Enrollment target
- 1
- Study location
NCT05926687: Recruiting Phase 2 study of Autism Spectrum Disorder and Autism, sponsored by Northwestern University.
NCT05926687 is a Phase 2 study of Autism Spectrum Disorder and Autism that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 184 participants, above the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (36% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05926687, a Phase 2 study of Autism Spectrum Disorder and Autism, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 184 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the proposed study is to: (a) determine how best to sequence two parent-mediated interventions: a social communication intervention (Project ImPACT, Improving Parents as Communication Teachers) and a disruptive behavior intervention (Parent Training for Disruptive Behavior) and (b) examine moderators and mediators of intervention outcomes.
Primary Outcome
The child's observed social communication is measured from a caregiver-child interaction in which the dyad interacts across a variety of daily activities using materials in their home. This interaction will be recorded and coded for the child's social communication using the codebook from the Early Communication Indicator assessment.
Conditions Studied
Interventions
- BEHAVIORAL Social Communication
- BEHAVIORAL Disruptive Behavior
- BEHAVIORAL Social Communication + Reduce Frequency
- BEHAVIORAL Social Communication + Add Tools
- BEHAVIORAL Disruptive Behavior + Reduce Frequency
Study Locations (1)
Illinois
- Northwestern University - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 184 participants |
| Start Date | 2023-07-11 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 2 |
What NCT05926687 shows while recruiting
NCT05926687 is an interventional study that assigns participants to a tested intervention. The registered 184 participants enrollment target is mid-sized for trials with a published cap, above the 135-participant average among 224 other Autism Spectrum Disorder trials with a reported enrollment target (36% higher).
The record links to 2 conditions, with Autism Spectrum Disorder appearing as the primary indexed condition, and to 5 interventions - of which Social Communication is the first listed.
NCT05926687 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05926687 about?
NCT05926687 is a clinical study titled "Optimizing Outcomes for Young Autistic Children". The overarching goal of the proposed study is to: (a) determine how best to sequence two parent-mediated interventions: a social communication intervention (Project ImPACT, Improving Parents as Communication Teachers) and a disruptive behavior intervention (Parent Training for Disruptive Behavior) a...
What is the current status of trial NCT05926687?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 184 participants. The study started on 2023-07-11. Estimated completion is 2027-02-28.
What conditions does trial NCT05926687 study?
This clinical trial studies the following conditions: Autism Spectrum Disorder, Autism.
What interventions are being tested in trial NCT05926687?
The interventions under investigation include: Social Communication (BEHAVIORAL), Disruptive Behavior (BEHAVIORAL), Social Communication + Reduce Frequency (BEHAVIORAL), Social Communication + Add Tools (BEHAVIORAL), Disruptive Behavior + Reduce Frequency (BEHAVIORAL).
Who is sponsoring clinical trial NCT05926687?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05926687 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Spectrum Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05926687's enrollment target sits among peer trials
184 46th of 224 higher than 179 of 224 other Autism Spectrum Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Autism Spectrum Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pimavanserin for Rigid-compulsive Symptoms in Autism Spectrum Disorder
RECRUITING · Phase 2
-
Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial
RECRUITING · Phase 2
-
Early Treatment of Language Impairment in Young Children With Autism Spectrum Disorder With Leucovorin Calcium
RECRUITING · Phase 2
-
Trial of Zolpidem for Sleep in Children With Autism
RECRUITING · Phase 2
-
Telehealth-Enabled Versus In-Person Parent-Mediated Behavioral Treatment for Challenging Behaviors in Children With ASD
RECRUITING · Phase 2
-
A Study of Esomeprazole in Children With Autism
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03903510 · 184 participants · NA
Virtual Reality During Pediatric Cast Removal
- NCT04020510 · 184 participants · Phase 4
Standard Injections Versus Reduced Injections for Intravesical onabotulinumtoxinA Treatment of Overactive Bladder
- NCT04135846 · 184 participants · Phase 2
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
- NCT04396873 · 184 participants · Phase 1
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI